Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Harpoon Therapeutics Inc
(NQ:
HARP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harpoon Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
7 Stocks to Add to Your 10x Watchlist
December 16, 2022
It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist.
Via
InvestorPlace
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 13, 2022
Via
Benzinga
Looking Into Harpoon Therapeutics's Recent Short Interest
December 13, 2022
Harpoon Therapeutics's (NASDAQ:HARP) short percent of float has risen 15.0% since its last report. The company recently reported that it has 563 thousand shares sold short, which is 3.22% of all...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 13, 2022
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday morning!
Via
InvestorPlace
Harpoon Therapeutics Shares Gain On Updated Data From Investigational Myeloma Drug
December 12, 2022
Via
Benzinga
Expert Ratings for Harpoon Therapeutics
August 11, 2022
Analysts have provided the following ratings for Harpoon Therapeutics (NASDAQ:HARP) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
December 13, 2022
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Via
Benzinga
Dow Surges Over 250 Points; Weber Shares Spike Higher
December 12, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday
Via
Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
December 12, 2022
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
Via
Benzinga
Stocks Hold Gains Ahead Of Tuesday's Economic Flurry
December 12, 2022
The major indexes are continuing their move higher this afternoon, as investors await tomorrow's release of November's consumer price index (CPI) data.
Via
Talk Markets
Three Small-Cap Biotech Stocks to Consider Now
December 12, 2022
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023
Via
MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session
December 12, 2022
Via
Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
December 12, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday
Via
Benzinga
Why Is Reborn Coffee (REBN) Stock Up 34% Today?
December 12, 2022
Reborn Coffee (REBN) stock is heating up on Monday as investors take note of the California coffee company's shares with heavy trading.
Via
InvestorPlace
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma
December 12, 2022
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development
Via
Spotlight Growth
Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?
December 12, 2022
Harpoon Therapeutics (HARP) stock is taking off on Monday following the release of updated results from its myeloma drug candidate.
Via
InvestorPlace
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
December 12, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 12, 2022
Via
Benzinga
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
December 11, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
December 09, 2022
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Via
Benzinga
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
November 03, 2022
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022,...
From
Harpoon Therapeutics
Via
GlobeNewswire
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
October 04, 2022
Harpoon adds experienced drug developer to leadership team
From
Harpoon Therapeutics
Via
GlobeNewswire
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Citigroup Maintains Buy Rating for Harpoon Therapeutics: Here's What You Need To Know
August 29, 2022
Citigroup has decided to maintain its Buy rating of Harpoon Therapeutics (NASDAQ:HARP) and lower its price target from $7.00 to $6.00. Shares of Harpoon Therapeutics are trading down 3.78% over the...
Via
Benzinga
Analyst Ratings for Harpoon Therapeutics
August 29, 2022
Over the past 3 months, 6 analysts have published their opinion on Harpoon Therapeutics (NASDAQ:HARP) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.